Whole-genomic Survey of Oligodendroglial Tumors: Correlation Between Allelic Imbalances and Gene Expression Profiles

Overview

Journal J Neurooncol

Publisher Springer

Date 2010 Sep 8

PMID 20820872

Citations 2

Authors

Ruben Ferrer-Luna

Lina Nunez

Jose Piquer

Eugenia Arias

Francisco Dasi

Andres Cervio

Naomi Arakaki

Gustavo Sevlever

Bernardo Celda

Horacio Martinetto

Affiliations

Soon will be listed here.

Abstract

Malignant gliomas are the most common subtype of primary central nervous system (CNS) tumors. Their pathological classification, however, remains subjective, stimulating researchers to actively seek objective molecular markers to discover alternative and more reproducible tools for improved subtypification. Herein, we present a global survey of genomic alterations in oligodendroglial tumors (OT). Genetic and epigenetic alterations identified in this study are correlated with OT molecular groups we have recently reported: a neurogenic group composed of tumors with loss of heterozygosity (LOH) at 1p-19q, IDH1 mutations, and MGMT promoter methylation, showing good prognosis; an intermediate group, presenting TP53 mutations or LOH at 17p, IDH1 mutations, and GSTP1 promoter methylation; and a proliferative group, presenting major genetic alterations (LOH at 10q, EGFR amplification, and CDKN2A/ARF deletion) and poor prognosis. These results allowed us to refine our molecular characterization associated with prognosis, referring exclusively to oligodendroglial tumors.

Citing Articles

Frequency and Prognostic Impact of CDKN2A/B Alteration in Oligodendrogliomas: Systematic Review and Meta-analysis.

Nakasu S, Deguchi S, Nakasu Y Neurol Med Chir (Tokyo). 2024; 64(12):442-450.

PMID: 39443123 PMC: 11729257. DOI: 10.2176/jns-nmc.2024-0105.

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis.

Lee K, Kim S, Kim E, Shim Y, Won J, Park C Sci Rep. 2023; 13(1):6761.

PMID: 37185778 PMC: 10130138. DOI: 10.1038/s41598-023-32153-y.

Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors.

Kuo L, Tsai S, Chang C, Kuo K, Huang A, Tsai J PLoS One. 2013; 8(6):e67139.

PMID: 23826216 PMC: 3691155. DOI: 10.1371/journal.pone.0067139.

References

French P, Swagemakers S, Nagel J, Kouwenhoven M, Brouwer E, van der Spek P . Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res. 2005; 65(24):11335-44. DOI: 10.1158/0008-5472.CAN-05-1886. View

Brandes A, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L . Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol. 2006; 24(29):4746-53. DOI: 10.1200/JCO.2006.06.3891. View

Palmisano W, Divine K, Saccomanno G, Gilliland F, Baylin S, Herman J . Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000; 60(21):5954-8. View

Bredel M, Scholtens D, Harsh G, Bredel C, Chandler J, Renfrow J . A network model of a cooperative genetic landscape in brain tumors. JAMA. 2009; 302(3):261-75. PMC: 4447713. DOI: 10.1001/jama.2009.997. View

Bleeker F, Atai N, Lamba S, Jonker A, Rijkeboer D, Bosch K . The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010; 119(4):487-94. PMC: 2841753. DOI: 10.1007/s00401-010-0645-6. View

Ehrich M, Nelson M, Stanssens P, Zabeau M, Liloglou T, Xinarianos G . Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A. 2005; 102(44):15785-90. PMC: 1276092. DOI: 10.1073/pnas.0507816102. View

Li C, Hung Wong W . Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2001; 2(8):RESEARCH0032. PMC: 55329. DOI: 10.1186/gb-2001-2-8-research0032. View

Nutt C, Mani D, Betensky R, Tamayo P, Cairncross J, Ladd C . Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003; 63(7):1602-7. View

Griffin C, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart J . Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol. 2006; 65(10):988-94. DOI: 10.1097/01.jnen.0000235122.98052.8f. View

10.

Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N . Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res. 2002; 8(1):196-201. View

11.

Benetkiewicz M, Idbaih A, Cousin P, Boisselier B, Marie Y, Criniere E . NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas. PLoS One. 2009; 4(1):e4107. PMC: 2606061. DOI: 10.1371/journal.pone.0004107. View

12.

Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D . Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007; 104(50):20007-12. PMC: 2148413. DOI: 10.1073/pnas.0710052104. View

13.

Kotliarov Y, Steed M, Christopher N, Walling J, Su Q, Center A . High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res. 2006; 66(19):9428-36. PMC: 4316202. DOI: 10.1158/0008-5472.CAN-06-1691. View

14.

Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A . PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol. 2009; 20(2):298-300. PMC: 8094690. DOI: 10.1111/j.1750-3639.2009.00327.x. View

15.

Ducray F, Idbaih A, De Reynies A, Bieche I, Thillet J, Mokhtari K . Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer. 2008; 7:41. PMC: 2415112. DOI: 10.1186/1476-4598-7-41. View

16.

Ferrer-Luna R, Mata M, Nunez L, Calvar J, Dasi F, Arias E . Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression. J Neurooncol. 2009; 95(3):343-354. DOI: 10.1007/s11060-009-9944-y. View

17.

Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E . Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol. 2007; 61(5):484-90. DOI: 10.1002/ana.21125. View

18.

Giannini C, Burger P, Berkey B, Cairncross J, Jenkins R, Mehta M . Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 2008; 18(3):360-9. PMC: 8095535. DOI: 10.1111/j.1750-3639.2008.00129.x. View

19.

Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway L . Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol. 2006; 2(5):e41. PMC: 1458964. DOI: 10.1371/journal.pcbi.0020041. View

20.

Paulin R, GRIGG G, Davey M, Piper A . Urea improves efficiency of bisulphite-mediated sequencing of 5'-methylcytosine in genomic DNA. Nucleic Acids Res. 1998; 26(21):5009-10. PMC: 147923. DOI: 10.1093/nar/26.21.5009. View